Association of TP53 Mutations with Response and Longer Survival under Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer

The emergence of immune checkpoint inhibitors (ICI) has significantly influenced clinical therapeutic strategies for most cancer subtypes, notably in advanced non-small-cell lung cancer (aNSCLC). Programmed cell death-1 (PD-1) inhibitors, such as nivolumab or pembrolizumab, and programmed cell death ligand-1 (PD-L1) inhibitors (e.g. atezolizumab) have significantly improved progression-free survival (PFS) and overall survival (OS) of patients with aNSCLC, achieving outstanding duration of disease control compared to standard platinum-based frontline chemotherapy or second-line docetaxel chemotherapy [1 –3].

Source: Lung Cancer - April 7, 2019 Category: Cancer & Oncology Authors: Sandra Assoun, Nathalie Theou-Anton, Marina Nguenang, Aur élie Cazes, Claire Danel, Baptiste Abbar, Johan Pluvy, Valérie Gounant, Antoine Khalil, Céline Namour, Solenn Brosseau, Gérard Zalcman Source Type: research